Oncology Billing - Medixcode

Expert Oncology Billing Services

Your Drug Inventory is Your Revenue. One Denied Claim Can Wipe Out the Margin.

A single denied Keytruda claim isn’t just paperwork. It’s $10,000 or more your practice already spent on that chemo drug, now sitting in limbo instead of your bank account. You’re not just billing for a service — you’re recovering money you’ve already spent on inventory.

Hero Image · 1 of 3

Oncology Billing Specialist at Work

Editorial portrait — a certified oncology medical coder at a clean desk reviewing a printed chemotherapy claim (CMS-1500) with J-code reference book (J9271 / J9299 / J9355) and JW/JZ compliance sheet. Warm side-window light.

Subject1 billing pro, neutral clothing (no scrubs / no lab coat)

SettingAdmin office, printed CMS-1500 + J-code manual visible

GradingDesaturated 20–25%, navy shadows, amber highlights

AvoidChemo bags, IV poles, infusion chairs, patients, PPE, screens

$10,000+

Per Denied Keytruda Claim

Get the units math wrong. Miss a JW or JZ modifier. Let a prior auth lapse.

Any one of these can turn a routine claim into a write-off. Our oncology billing services built specifically for community oncology practices exist for exactly this reason: to protect the drug revenue you’ve already put on the line.

About the Work

You're Recovering Money You've Already Spent on Inventory

A single denied Keytruda claim isn’t just paperwork. It’s $10,000 or more your practice already spent on that chemo drug, now sitting in limbo instead of your bank account. You’re not just billing for a service — you’re recovering money you’ve already spent on inventory.

Editorial Photo

J-Code Units Verification Close-Up

Close-up shot of an oncology coder’s hands reviewing a printed CMS-1500 chemotherapy claim, J-code manual, and NDC reference sheet on a clean desk.

FocusHands + paperwork, no face — document-first composition

Ratio16:9 landscape rectangle, 340px section height

PaletteWarm cream desk, amber ambient, navy shadow tint

AvoidChemo bags, IV lines, infusion chairs, patients, PPE, screens

Why Oncology Is Different

Why Oncology Billing is the Highest-Stakes Specialty in Medicine

Most billing companies treat oncology like any other specialty. It isn’t. Here’s why practice administrators lose sleep over this one.

The units conversion trap.

Say you administer 200mg of a drug, but the J-code bills in 10mg increments. That’s 20 units, not 200. Get that math wrong on a high-cost drug and you’re underpaid by thousands of dollars, on every single claim, every single time.

JW and JZ modifier compliance.

Since 2023, every claim involving a single-dose vial needs a JW modifier (you had leftover chemo drug and wasted it) or a JZ modifier (you used the whole vial, no waste). Miss it, and the claim gets rejected outright. This isn’t optional anymore. It’s mandatory on every applicable claim.

Buy-and-bill economics are razor-thin.

Your practice buys the chemo drug, administers it, then bills insurance. Medicare pays ASP plus 6%, the average sales price plus a small markup. But factor in sequestration cuts, and that margin shrinks to around 4.3%. There’s almost no room for error.

White bagging is eating into your margin.

When a payer forces your practice to use their specialty pharmacy instead of your own inventory, you lose the buy-and-bill margin entirely. Your billing team needs to track which payers are doing this, and when it’s worth pushing back.

Prior auth delays are getting worse.

Patients can’t wait weeks to start treatment. But payers, especially Medicare Advantage plans, keep adding prior auth requirements on the most expensive oncology drugs.

Infusion & Radiation Coverage

Simplify Complex Infusion and Radiation Billing

Our chemotherapy billing services cover chemotherapy infusion billing, chemotherapy administration codes, sequential infusion, and radiation oncology billing with precision. Whether your infusion suite follows a buy-and-bill model or works with a specialty pharmacy, we ensure every claim reflects accurate documentation and payer-specific billing requirements.

Team Photo

Oncology RCM Team Reviewing Drug Claims

Editorial scene of 2–3 oncology billing / RCM specialists at a shared table reviewing printed chemotherapy claims (CMS-1500), a J-code and NDC reference book, and JW/JZ compliance chart. Focused conversation, hands on paperwork.

Subject2–3 admin/billing pros on printed drug-claim documentation

Ratio16:9 landscape rectangle, 340px section height

GradingDesaturated 20–30%, warm highlights, cinematic mid-tones

AvoidChemo bags, IV lines, infusion chairs, exam rooms, PPE, screens

How We Protect Your Revenue

Community Oncology Practices Lose More Revenue to Quiet Underpayments Than to Outright Denials

A denial is loud. It shows up in your reports and gets worked. An underpayment is silent. The claim pays, just not enough, and it’s easy to miss unless someone’s actively comparing expected reimbursement against what actually landed.

We make sure every dollar you spent on drug inventory comes back to you.

Drug units verification on every claim.

We catch units and dosage math errors before the claim ever goes out the door, not after the denial arrives.

JW and JZ modifier management.

We track compliance claim by claim, so wastage documentation and zero-waste attestations never get missed.

A prior auth team focused on oncology drugs.

Because a delayed authorization is a delayed treatment, not just a delayed payment.

Underpayment detection.

We compare what you actually received against what you should have received, broken down by drug and by payer, so quiet underpayments don’t slide by unnoticed.

Underpayment recovery on infusion claims.

When we find a gap, we don’t just flag it. We appeal it, track it through resolution, and report back on what was recovered.

Want us to audit your top 5 J-codes for underpayments?

Get a free oncology billing assessment and see exactly where the money’s going.

EOM · Biosimilars · Codes

EOM, Biosimilars, and What's Changing in Oncology Billing

The Enhancing Oncology Model has been extended through June 2030, and it’s reshaping how community oncology practices get paid. Participating practices receive Monthly Enhanced Oncology Services payments:

$110 / bene / mo

MEOS Base Rate

Base-rate Monthly Enhanced Oncology Services payment per beneficiary per month for participating practices.

$140 / bene / mo

Dually Eligible Rate

Rising to $140 per beneficiary per month for dually eligible patients under the extended EOM.

At the same time, payers are pushing biosimilar-first policies across the board. That means your billing team needs to manage Q-code switches carefully, or risk denials tied to the wrong biosimilar code. Get the codes right, and you protect your revenue and your standing under EOM at the same time.

Code

What It Means

96413 / 96415

First hour / each additional hour of IV chemo infusion

96417

Sequential infusion of a different drug

96409 / 96411

IV push chemo administration

J9271

Pembrolizumab (Keytruda)

J9299

Nivolumab (Opdivo)

J9355

Trastuzumab (Herceptin)

Modifier for reported drug wastage

Modifier attesting to zero drug wastage

Results That Matter

The Results Community Oncology Practices See

We track performance the way you do: in dollars recovered and claims paid, not billing jargon.

✓

Higher drug claim approval rates on first submission

✓

Units accuracy rate across every high-cost drug claim

✓

JW/JZ compliance rate tracked claim by claim

✓

Denial overturn rate on appealed drug claims

✓

Lower days in A/R, so cash flow keeps pace with drug purchasing

⏱

A quick note on timelines: oncology billing is one of the most competitive specialties to rank for online, so if you found this page through search, expect a realistic 4–6 month runway before you see it climb. What sets us apart in that time is depth in the Enhancing Oncology Model and buy-and-bill economics that most billing companies simply don’t have.

Compliance · Recovery · Reimbursement

Three Areas Where We Move the Needle Every Month

Stay Ahead of Changing Oncology Compliance

Successful hematology oncology billing services require strict compliance with JW modifier drug wastage billing, JZ modifier requirements, single-dose vial documentation, and prior authorization oncology drugs. We also support Enhancing Oncology Model billing, follow NCCN guidelines, and optimize biosimilar billing reimbursement using the correct biosimilar Q-codes for cleaner claims.

Recover More Revenue While Reducing Financial Toxicity

From oncology billing for private practice to enterprise groups, our outsourced oncology billing team strengthens oncology denial management, underpayment recovery oncology infusion, and buy and bill oncology workflows. We also address challenges like white bagging, brown bagging, and connect eligible patients with patient assistance programs to reduce financial toxicity.

Stop Losing Revenue on High-Cost Cancer Therapies

Every chemotherapy claim involves more than coding. Accurate oncology medical billing depends on correct J-code billing oncology drugs, drug units calculation, and NDC requirements oncology claims. As an experienced oncology billing company, we help providers maximize drug reimbursement, support oncology revenue cycle management, and reduce costly payment delays.

FAQs

Frequently Asked Questions

Common oncology billing questions we hear from community oncology practices.

What is the JZ modifier?

The JZ modifier tells the payer you administered an entire single-dose vial with zero drug wastage. It’s been required since 2023 on applicable claims. Without it, or without the JW modifier when there is waste, the claim can be rejected before it’s even reviewed.

How do you bill for chemo drug wastage?

You use the JW modifier to report any leftover drug from a single-dose vial that couldn’t be used on another patient. It documents the wasted amount separately from the administered dose, so you get reimbursed for the full vial, not just what the patient received.

What is buy-and-bill in oncology?

Buy-and-bill means your practice purchases the chemotherapy drug, administers it in-office, and then bills the payer for reimbursement. Medicare typically pays ASP plus 6%, though sequestration trims that down. It’s how most community oncology practices keep drugs on hand for immediate treatment.

Why are oncology claims denied?

The most common reasons are units calculation errors, missing JW/JZ modifiers, incomplete prior authorizations, and NDC reporting mistakes. Because oncology drugs are so expensive, even small documentation gaps trigger denials that generalist billing teams often miss.

How much do oncology billing services cost?

Pricing varies by practice size and claim volume, and most oncology billing companies charge a percentage of collections. The bigger question is return: recovering even one or two underpaid drug claims a month typically covers the cost many times over.

Free Oncology Billing Assessment

Ready to See Where Your Drug Revenue is Leaking?

Get a free oncology billing assessment. We’ll audit your top J-codes for underpayments, verify your JW/JZ compliance, and show you exactly where the money should be landing.